Plasma cell myeloma
Not yet recruitingDapagliflozin for Primary Cardioprotection in Newly Diagnosed Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation – A Randomized Phase 2 Study
Dapagliflozin for Primary Cardioprotection in Newly Diagnosed Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation – A Randomized Phase 2 Study
- Disease:Plasma cell myeloma
- Substances:Dapagliflozin
Poland- Participants:18–64 years · 65+ years
- Substances:Dapagliflozin
- Sponsor:Instytut Hematologii I Transfuzjologii










